Investors faced a rough ride as Helix BioPharma Corp. saw a significant drop in stock value.
Helix BioPharma Corp. (HBP.TO) experienced a notable decline in its stock price during yesterday's trading session, closing down by 6.36%. This drop raises questions about the company's short-term stability and investor sentiment.
Advertisement
Helix BioPharma Corp.
HBP.TO
HBP.TO
Helix BioPharma Corp.
WealthAwesomeMarket cap
$78.67M
52W high
$5.40
52W low
$0.97
1W change
-28.97%
Beta
-0.27
Analyst Price Targets
Based on analyst covering HBP · as of Sep 17, 2026
Wall Street analysts forecast HBP stock price to rise 142.7% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$2.50
+142.7% Upside
Current Price
C$1.03
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on HBP's historical volatility
30-Day Vol
97.1%
Annualized
90-Day Vol
68.4%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$0.86
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.97 | C$0.69 – C$1.36 |
| 60 trading days | C$0.91 | C$0.57 – C$1.47 |
| 90 trading days | C$0.86 | C$0.48 – C$1.54 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: With a market cap of approximately CA$78.67 million and no profit margins reported, investors should be cautious about Helix BioPharma's financial health and future prospects.
6.36% drop in stock price
Helix BioPharma's stock fell to CA$1.03, highlighting investor concerns amidst a challenging financial landscape.
Bull case
If Helix BioPharma can successfully tackle its financial challenges and make progress with its therapeutic programs, there could be a chance for recovery and growth in its stock price.
Bear case
The recent drop in stock value reflects ongoing worries about the company's profitability and market position, which could keep investors on the sidelines for now.
Performance Overview
Advertisement
In yesterday's trading session, Helix BioPharma Corp. saw its stock price fall by 6.36%, closing at CA$1.03. This decline is particularly concerning given the company's current market cap of CA$78.67 million and lack of profitability.
Investor Sentiment
The drop in Helix BioPharma's stock price has raised alarms among investors, reflecting a broader concern about the company's ability to execute its business strategy effectively. With no recent positive news to boost confidence, many investors are reassessing their positions.
Looking Ahead
As Helix BioPharma navigates its financial landscape, investors will be closely watching for any updates regarding its therapeutic programs and financial health. The company has a long road ahead to restore investor confidence and stabilize its stock price.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
